European Companies Search Engine
EU funding (€16M): Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing Hor1 Nov 2024 EU Research and Innovation programme "Horizon"
Overview
Text
Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing
PHARMECO is supported by the Innovative Health Initiative Joint Undertaking (IHI JU). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe. The project's overall objective is to revolutionize pharmaceutical manufacturing towards sustainability by integrating environmentally friendly technologies/processes and harmonized sustainability assessments methods into healthcare industry practices. This encompasses early design phase, operation, and eventual use and disposal. The project's first objective is to enhance the early-stage development of pharmaceutical products by implementing Sustainable-by-Design (SSbD)-driven process-intensified platforms (e.g. continuous manufacturing). This involves designing sustainable processes based on so-called SELECT (Safety, Environment, Legal, Economy, Control and Throughput) criteria and setting up eco-friendly systems for producing small molecules, peptides, oligo-nucleotides, proteins and ribonucleic acid (RNA) with advanced control measures. Next, PHARMECO aims to scale up and demonstrate environmentally-friendly processes for industrial manufacturing and decontamination, which includes creating infrastructure for studying key unit operations with sustainable technology and for SSbD-driven process intensified manufacture at a scale sufficient for clinical testing and a manufacturing process that is easily transferred to a Good Manufacturing Practice (GMP) environment. PHARMECO also aims to steer the development of (bio)manufacturing processes towards sustainable production through digital decision-making tools. This involves creating a modular digital tool for assessing sustainability from multiple perspectives, evaluating practices. Finally, the project seeks to establish a standardized approach for assessing the environmental sustainability of pharmaceuticals, which involves collaboration with various stakeholders to create scientifically robust guidelines, applying consistent Life Cycle Assessment (LCA) methodologies, and facilitate regulatory adoption of standardized LCA practices. By integrating sustainability considerations into every phase of manufacturing, PHARMECO will positively revolutionize pharmaceutical industry.
Funded Companies:
Source: https://cordis.europa.eu/project/id/101165889
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
The visualizations for "ABBVIE DEUTSCHLAND GmbH & Co. KG - EU funding (€16M): Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
